Contents

Acknowledgments xi
Introduction xiii
List of Contributors xv

SECTION I: The Health Care Environment and Medications 1

1. FDA Reform: Déjà vu Encore 3
   John J. Cohrssen
   1.1 Introduction 4
   1.2 The 1992 prescription drug user fee act adds funds and changes FDA’s focus 7
   1.3 PDUFA shortens drug review times and eliminates the drug lag 8
   1.4 PDUFA timetables feed safety concerns 9
   1.5 FDA responds to safety concerns 11
   1.6 The pipeline problem 12
   1.7 The 2007 FDA Science Board’s Subcommittee on Science and Technology report 17
   1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative 18
   1.9 The impact of PDFUA on FDA 21
   1.10 Comparative medical benefits, comparative effectiveness and FDA 21
   1.11 FDA and non-inferiority trials 23
   1.12 FDA and CMS decisions on Medicare coverage 24
   1.13 Preemption: FDA’s role in relation to liability litigation in state courts 24
   1.14 FDA’s exclusivity in allowing access to experimental drugs 24
   1.15 Conclusions 25

2. Do Antidepressants Cause Suicide? 31
   Marc Hertzman
   2.1 Some definitional problems 31
CONTENTS

2.2 A brief history of the concerns of suicidality caused by antidepressants 32
2.3 Politics rears its ugly head 35
2.4 The FDA responds 35
2.5 What changes in public policy wrought 36
2.6 A funny thing happened on the way to the forum 39
2.7 Meanwhile back at the ranch 39
2.8 Moral (maybe) 40

3. The Genome, Genes and Brain – Tailored Drugs 43
Lawrence Adler
3.1 Introduction 43
3.2 Issues in new drug development 44
3.3 Early development of psychiatric pharmaceutical entities 44
3.4 Advances in research technology 45
3.5 Review of genetics 46
3.6 Activation of genes by signal transduction cascades 47
3.7 The human genome 48
3.8 The sequencing of the genome 48
3.9 DNA variation 48
3.10 Genes and illness 49
3.11 Genomic findings, potential targets and new drug development 50
3.12 Conclusion 55

4. Patenting and Licensing Concerns in Psychiatric Genetics 61
Jorge A. Goldstein and Karen R. Markowicz
4.1 Genetic diagnoses in psychiatry 62
4.2 The evolving patent landscape in psychiatry 63
4.3 Approaches to solving potential problems 76
4.4 Conclusions 83

5. Women’s Issues in Clinical Trials 87
Mary V. Seeman
5.1 History 87
5.2 Perceived advantages of excluding women 90
5.3 Change in perspective 90
5.4 Have things changed? 91
5.5 Progress since 1993 92
5.6 Reported current difficulties in including women 93
5.7 Contraception in clinical trials 94
5.8 Drugs in lactating women 95
5.9 How often do women take drugs during pregnancy? 96
5.10 Ethical issues: risk/benefit analysis 96
## CONTENTS

5.11 Adequate information 97  
5.12 Adolescent women 97  
5.13 Recruitment and retention of women 97

### SECTION II: Clinical Trials and Mood Disorders 103

6. Issues and Clues in the Pharmacological Treatment of Mood Disorders 105  
*Fabrice Jollant, Adéla Ionita and Philippe Courtet*

- 6.1 What do we know about mood disorders that may be relevant for their pharmacological treatment? 106  
- 6.2 Are there clues for the pharmacological treatment of mood disorders? 109  
- 6.3 Perspectives 116

7. Bipolar Disorder 125  
*Alberto Bocchetta*

- 7.1 Introduction 126  
- 7.2 Trials in acute mania 127  
- 7.3 Trials in acute bipolar depression 130  
- 7.4 Trials in maintenance of bipolar disorder 132  
- 7.5 What is a mood stabilizer? 134  
- 7.6 What controlled trials cannot tell us about treatment of bipolar disorder 135

8. Special Issues of Research Methodology in Bipolar Disorder Clinical Treatment Trials 149  
*Robert M. Post*

- 8.1 Introduction 150  
- 8.2 Efficacy–effectiveness gap 151  
- 8.3 Trials for drug registration versus those that are most clinically informative 151  
- 8.4 The need for designs that more optimally inform clinical practice 152  
- 8.5 ‘Hidden’ high degrees of treatment resistance 153  
- 8.6 Controversy about optimal designs and rating instruments 154  
- 8.7 The traditional RCT is expensive, cumbersome and prone to failure 156  
- 8.8 Alternative designs for pilot and proof of principle efficacy studies 156  
- 8.9 Statistical analysis of N-of-1 trials 159  
- 8.10 Statistical approaches to estimating necessary trial durations in individual patients 160  
- 8.11 Crossover trials for enhancing clinical informatics and statistical power 161  
- 8.12 Carryover effects 164  
- 8.13 Long-term trend in studies of bipolar disorder compared to other major mental disorders 165
CONTENTS

8.14 Parallel and pressing design issues for childhood-onset bipolar illness 166
8.15 Contradictory balance between inclusiveness (for generalizability) and homogeneity (for efficacy) 167
8.16 Assessing moderators and mediators 167
8.17 Conclusions and implications 169

9. The Utility of Low-dose Antidepressants 179
Monica L. Zilberman, Clarice Gorenstein and Valentim Gentil

9.1 Introduction 179
9.2 Low dose antidepressants for chief indications 180
9.3 Antidepressant use for other indications 180
9.4 Emotion regulation in healthy individuals 184
9.5 Conclusion 185

SECTION III: Clinical Trials in Anxiety and Other Disorders 189

10. Clinical Trials for Anxiety Disorders 191
Marco Mula and Gionata Strigaro

10.1 Introduction 191
10.2 Methodological issues in treatment research for anxiety disorders 192
10.3 Panic disorder with/without agoraphobia 197
10.4 Generalized anxiety disorder 198
10.5 Social anxiety disorder 199
10.6 Post-traumatic stress disorder 200
10.7 Conclusions 201
10.8 Acknowledgment 202

11. Pharmacological Trials for the Treatment of Substance Use Disorders 207
Lisa J. Merlo, Julia Arana and Amanda M. Stone

11.1 Psychopharmacological trials for the treatment of substance use disorders 208
11.2 Definitions of substance use disorders 208
11.3 Introduction to psychopharmacotherapy for SUDs 209
11.4 Considerations in pharmacotherapy trials for SUDs 219
11.5 Conclusions and future directions 227

12. Clinical Psychopharmacology of Patients with Eating Disorders 233
James E Mitchell, Kristine Steffen, Scott Engel, Ross Crosby and James Roerig

12.1 Introduction 233
12.2 Diagnostic issues 234
13. **ADHD Clinical Trials** 251

*Ann Childress*

13.1 Introduction 251
13.2 Lisdexamfetamine (Vyvanse) 253
13.3 Methylphenidate transdermal system (Daytrana) 255
13.4 Dexmethylphenidate (Focalin) 256
13.5 Dexmethylphenidate extended release (Focalin XR) 257
13.6 Atomoxetine (Strattera) 259
13.7 Extended release methylphenidate (Ritalin LA) 261
13.8 Modified release methylphenidate (Metadate CD) 261
13.9 Mixed amphetamine salts extended release (Adderall XR) 262
13.10 OROS methylphenidate (Concerta) 264
13.11 Guanfacine extended release 266
13.12 SPD465 267
13.13 Modafinil 267
13.14 Bupropion XL 268
13.15 Discussion 269

14. **Autism and Asperger’s Spectrum Disorders** 273

*Marc Hertzman*

14.1 Introduction 273
14.2 Individual entities versus a spectrum disorder 274
14.3 Recent psychopharmacological approaches to autism and Asperger’s spectrum disorders 277
14.4 Recapitulation 283

15. **Pharmacological Treatments of Impulse Control Disorders** 289

*Helga Myrseth and Ståle Pallesen*

15.1 Impulse control disorders 289
15.2 Pathological gambling 291
15.3 Trichotillomania 292
15.4 Kleptomania 299
15.5 Pyromania 301
15.6 Intermittent explosive disorder 304
15.7 Conclusions 304